| SKB565 for Injection in Advanced Solid Tumors (NCT07545265) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-09-01 |
| SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer (NCT07697586) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-08-07 |
| A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) (NCT07622186) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-07-31 |
| A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants (NCT07668154) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-07-31 |
| SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma (NCT07700667) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-07-30 |
| A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma (NCT07732023) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-07-20 |
| SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma (NCT07609667) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-06-30 |
| SKB118 Injection in Advanced Solid Tumors (NCT07586943) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-06-01 |
| A Study of SKB571 in Participants With Gastrointestinal Tumors (NCT07564466) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-05-20 |
| A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors (NCT07448922) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-04-08 |
| A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities (NCT07308106) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-04-03 |
| A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants (NCT07488065) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-03-31 |
| Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NCT07329322) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-03-30 |
| Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma (NCT07324629) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-03-13 |
| SKB105 for Injection in Advanced Solid Tumors (NCT07380386) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-03-05 |
| SKB500 Combinations in Patients With Small Cell Lung Cancer (NCT07296809) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-01-30 |
| A Phase II Study of SKB571 in Patients With Lung Cancer (NCT07230405) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-01-19 |
| Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC (NCT07341100) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2026-01-16 |
| A Study of SKB518 in Patients With Lung Cancer (NCT07019675) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2025-08-29 |
| A Study of SKB107 in Advanced Solid Tumors With Bone Metastases (NCT07087197) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2025-08-15 |
| A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy (NCT07071337) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2025-07-18 |
| SKB445 for Injection in Solid Tumors (NCT06826040) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2025-02-05 |
| A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors (NCT06725381) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2024-12-17 |
| A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors (NCT06736327) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2024-12-13 |
| A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors (NCT06726369) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2024-12-12 |
| A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NCT06670196) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2024-11-27 |
| A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NCT06711900) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2024-10-30 |
| A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer (NCT07299825) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2024-09-20 |
| A Study of SKB518 in Patients With Advanced Solid Tumors (NCT06428331) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2024-07-04 |
| A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT06448312) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2024-06-07 |
| A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer (NCT06279364) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2024-02-28 |
| Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer (NCT06081959) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2023-10-31 |
| A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy (NCT06968585) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2023-07-18 |
| SKB410 for Injection in Solid Tumors (NCT05906537) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2023-07-06 |
| A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients (NCT05870319) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2023-06-26 |
| SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors (NCT05631262) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2022-11-30 |
| A Study of KL130008 in Adults With Severe Alopecia Areata (NCT05496426) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2022-11-09 |
| A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors (NCT05549804) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2022-08-30 |
| SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer (NCT05445908) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2022-08-17 |
| SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (NCT05347134) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2022-06-10 |
| A Study of KL340399 in Patients With Advanced Solid Tumors (NCT05387928) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2022-06-07 |
| SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. (NCT05351788) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2022-05-20 |
| A Study of SKB315 in Patients With Advanced Solid Tumors (NCT05367635) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2022-03-16 |
| A Study of KL590586 in Patients With Advanced Solid Tumors (NCT05265091) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2021-09-15 |
| Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC (NCT04835142) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2020-12-31 |
| KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma (NCT03848286) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2019-03-06 |
| A Study of A166 in Patients With Advanced Solid Malignant Tumors (NCT05311397) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2018-08-09 |
| An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma (NCT03580564) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2018-08-01 |
| Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial (NCT03426371) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2018-03-18 |